News
Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...
Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...
Moderna's Spikevax vaccine has been fully approved for children with high-risk conditions, the first vaccine to do so.
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
StockStory.org on MSN13h
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Moderna 57, a new Italian restaurant next to the Syosset train station, offers over 100 dishes to diners. The owner, Paul ...
Enphase Energy (ENPH) retained its spot as the most shorted S&P 500 (SP500) stock as a percentage of float in June, followed ...
This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...
Sioux City put a damper on Cleburne’s series-winning streak as the Railroaders dropped all three games to the Explorers over ...
The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...
GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results